Idiopathic Parkinson's disease (IPD) is a progressive neurodegenerative disorder for which no restorative or neuroprotective therapy is available. Interest has recently been directed to association studies on polymorphisms of various genes, mainly those related to dopamine metabolism and transport, and their effect on response to PD, which includes primarily levodopa and dopaminomimetics. Approximately 15-20% of patients with PD do not respond to levodopa, and the majority of those who do respond develop adverse fluctuations in motor response, primarily levodopa-induced dyskinesias. This review summarizes the influence of polymorphisms in various genes on the relative risk of IPD and on levodopa efficacy. It focuses on the importance of well-designed polymorphism studies that include large samples of patients with IPD and tightly matched controls and use identical methodologies. Valid data on such polymorphisms might increase the efficacy of levodopa, decrease its side effects, and reduce the occurrence of levodopa-induced dyskinesias. They might also provide a novel diagnostic tool for PD.
Introduction Idiopathic Parkinson's disease (IPD) is a progressive neurodegenerative disease for which no restorative or neuroprotective therapy is available. It is characterized by continuous cell loss in the nigrostriatal system -about 10% per year by positron-emission tomography (PET). 1, 2 In recent years, evidence highlighting the importance of the interaction between environmental factors and genetics has prompted a large number of association studies on the role of gene polymorphisms in the relative risk of IPD. Candidate genes were selected on the basis of the current understanding of the pathophysiology of IPD and include mainly genes that are linked to dopamine synthesis, transport, and degradation, detoxification of xenobiotics and other toxins in dopaminergic neurons and mitochondrial metabolism, and also genes that encode for essential transcription factors or neurotrophic factors involved in the development of the mesencephalic dopaminergic system. In addition, a number of association studies suggested that functional polymorphisms might affect the phenomenon of 'levodopa-nonresponse' and levodopa-induced motor fluctuations, mainly levodopa-induced dyskinesia.
The aim of the present review was to summarize the polymorphism-association studies on IPD performed to date, with emphasis on the influence of polymorphisms in dopamine-related genes on the efficacy of levodopa. We searched the Medline database (PubMed) from January 1954 to January 2004 using the key words 'PD', 'polymorphism', and 'levodopa'. The search was augmented by a review of the references cited in the articles identified. Only studies with two or more independent investigations of a specific gene, or gene-family polymorphism in patients with clinically and/or pathologically well-diagnosed IPD and matched (age, gender, and ethnicity) controls (healthy or without clinical evidence of neurodegeneration disease), were included. The genes whose polymorphisms have already been studied in relevance to IPD risk and genes that should be examined were summarized in Table 1 . The genes that have been studied were subdivided into those confirmed via meta-analysis, and those that were not confirmed by meta-analysis. The genes that were not confirmed by meta-analysis were further divided into those which fulfilled the Lohmueller et al criteria for replication in metaanalysis, 3 and those which did not (see Table 1 ). This review addresses some of the difficulties in interpreting of the results and provides recommendations for designing novel polymorphism-association studies in the future.
Genetic variations with potential effect on PD risk: dopamine metabolism Dopamine receptors
The dopamine receptors are one of the most studied groups for polymorphism and IPD risk. There are five types. The D1 receptors include types D1 (DRD1) and D5 (DRD5) and the D2 receptors include types D2 (DRD2), D3 (DRD3), and D4 (DRD4). All are located in the striatum and are primarily involved in the dopaminergic response in PD. 4, 5 The D2 receptors mediate the motor effects of central dopamine stimulation. The genes for the five receptors are found on four separate chromosomes. [6] [7] [8] [9] [10] Each type contains seven transmembrane domains with a unique binding site formed by the external loops of the protein.
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DRD2: There are nine studies on DRD2 polymorphism in PD. Of the three studies that investigated the 141C Ins/Del and Ser311/Cys311 variants, [12] [13] [14] two showed a significant difference in allelic frequencies between patients with PD and control subjects, whereas the third failed to find any such association. 12 The first two studies 13, 14 also examined the A1 allele of the TaqIA polymorphism, and the B1 allele of the TaqIB polymorphism, and found that they were more frequent in patients with PD than in control subjects: Patients carrying the A1 or B allele had an increased risk of developing PD. Two other studies of the same polymorphism did not find any association with PD, 15, 16 with or without the combination of genotypes for intron 13 of 16 the dopamine-deactivating enzyme. nor was there an association of smoking and PD risk with the presence of these polymorphisms.
The remaining four studies examined the polymorphic dinucleotide repeat in the second intron of the DRD2 gene, [17] [18] [19] [20] but only two of them 18, 20 found a significant association between this polymorphism and PD in Caucasians.
Together, these findings imply that the DRD2 polymorphism might be involved in the risk of PD, but more studies and well-designed meta-analysis are needed for verification (see also Table 1) .
DRD4: Five studies examined the 48 base-pair tandem repeat polymorphism in exon 3 of the DRD4 gene. 12, 17, [21] [22] [23] Only one reported a significant association, namely, a higher rate of repeat numbers 6-7 in PD patients (n ¼ 95) those controls (n ¼ 47) in the Chinese population. 23 These results, together with the meta-analysis performed by Tan et al, 24 suggest that the DRD4 does not play a major role in PD (see Table 1 ).
Dopamine transporter
The dopamine transporter (DAT) is normally present in the terminals of neurons originating in the substantia nigra. It has been shown to confer 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) toxicity to non-neuronal cell cultures by allowing uptake of the 1-methyl-4-phenylpyridinium ion [MPP( þ )]. 25 The DAT gene contains a variable number tandem repeat (VNTR) in the 3 0 -untranslated region. Between three and 11 copies of this 40-bp repeat element are found in normal populations. 26 Of the five early studies that examined this polymorphism in the DAT gene, 12, 18, [27] [28] [29] the Australian study 28 showed an association of the 11-copy allele with a 10-fold increase in the risk of IPD. In the studies conducted more recently, the rare 11-copy allele was found to occur more often in PD patients in the Korean population 30 and in Chinese patients (n ¼ 171 31 and n ¼ 180 32 ) compared to control subjects (n ¼ 128 31 and n ¼ 85 32 , respectively). However, these findings were not confirmed in two other studies, 33, 34 which revealed that the homozygote 10-copy genotype of VNTR may confer protection against PD, but only in males. 34 Four studies examined the 1215A/G polymorphism located in exon 9, [35] [36] [37] [38] but only two of them, both from Japan, noted a significant decrease in the 1215G polymorphism in patients with PD compared to controls. 35, 36 Overall, the results so far, including the meta-analysis performed, 24 concerning the DAT polymorphism and the risk of PD remain equivocal.
Tyrosine hydroxylase
The tyrosine hydroxylase (TH) gene encodes for the ratelimiting enzyme in catecholamine synthesis. The two control studies conducted to date on the involvement of functional polymorphisms of the TH gene in the pathogenesis of PD found no significant allelic or genotypic association of IPD with the Val 81Met polymorphism. 39, 40 Although only two studies were performed, TH polymorphism does not seem to be involved in IPD susceptibility.
Dopamine beta hydroxylase
Two studies examined the correlation of dopamine hydroxylase (DBH) gene and polymorphism with susceptibility to PD. 41, 42 The first failed to show any significant association. 41 The other one, however, found that the allelic frequency of A2 allele and the genotypic frequency of A2/A2 genotype of the DBH gene were significantly higher in PD patients in the Shanghai Chinese Han population (Po0.01), and that the risk of suffering from PD increased in individuals with the A2 allele. At the same time, the allelic frequency of the A1 allele and the genotypic frequency of the A1/A2 genotype were significantly lower in PD patients (Po0.01).
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DBH is an enzyme that catalyzes the reaction of dopamine to adrenaline. Therefore, it seems reasonable to suggest that polymorphism in this enzyme might alter its activity and reduce dopamine levels in the brain. However, neurons that express TH and DBH are defined as noradrenergic neurons only, 43 and therefore the relevance of this polymorphism and PD risk is doubtful.
Monoamine oxidase (MAO)
The monoamine oxidase (MAO) enzyme oxidizes various physiologically and pathologically important monoamine neurotransmitters and hormones, such as dopamine, noradrenaline, adrenaline, and serotonin. There are two types of MAO -type A (MAO-A) and type B (MAO-B) -each with different bioactivities.
Monoamine oxidase A (MAO-A)
Three of the nine existing of MAO-A polymorphism in PD examined the (GT)n dinucleotide repeat in intron 1 of the MAO-A locus on the X chromosome. 18, 44, 45 One found that the polymorphic 122 allele appeared three times more frequently in patients with PD (n ¼ 91) than in control subjects (n ¼ 129). 44 The second study reported that 119 allele appeared 10 times more frequently in men with PD (n ¼ 30) compared with control subjects (n ¼ 102). 45 The third study did not find any association. 18 Two separate studies, of which one examined the (GT)n dinucleotide repeat in intron 2 of MAO-A locus on the X chromosome, and the other examined the RLFP with EcoRV polymorphism, found no differences in the distributions of any MAO-A alleles between PD patients and controls. 46, 47 A very recent work found that PD patients had higher frequencies of the G allele and the GG genotype, and lower frequencies of the TT genotype, than controls. When patients were divided into two groups by age of onset, significant differences in the allelic and genotypic frequencies were observed only between the early-onset PD subgroup and the control group; when patients were grouped by sex, a significant difference was observed only between the male PD subgroup and the male controls. 48 By contrast, three other recent studies failed to observe any such differences in the allelic or genotypic frequency of MAO-A. 16, 49, 50 
Monoamine oxidase B (MAO-B)
In all, 17 Seventeen studies examined the MAO-B polymorphism. Of them, 10 focused on the G/A polymorphism in intron 13 of the gene, of which four reported a significant positive association with PD in Caucasian and Japanese populations; 47, [51] [52] [53] the others found no association. 33, 46, [54] [55] [56] [57] The remaining seven studies examined the (GT)n dinucleotide repeat in intron 2 of the gene. Two studies found that the frequency of alleles 186 and 188 or 180 was higher in PD patients in relevance to controls in Caucasian and Australian populations, respectively. 44, 58 The remaining investigations did not find any positive association between the presence of the polymorphism and either PD 18, 46, 59 or the interaction of PD with smoking. 57, 60 According to these and other results, 24 it seems that MAO-A polymorphism and the G/A polymorphism in intron 13 of the MAO-B genes are not associated with IPD susceptibility, while the 4188 bp allele of MAO-B polymorphism might confer IPD susceptibility (see Table 1 ). Some of the between-study differences may be due, in part, to differences in methodologies and in the polymorphisms studied.
Catechol-O-methyltransferase (COMT)
One of the most studied enzymes in patients with PD is catechol-O-methyltransferase (COMT). COMT inactivates neurotransmitters, hormones, potentially toxic metabolites, and xenobiotics containing a catechol moiety by enzymatic methylation. [61] [62] [63] Its activities include the catalyzation of levodopa degradation to 3-O-methyldopa (3-OMD) in the periphery and brain. IT also catalyzes dopamine degradation to 3-methyoxythyramine (3-MT), and degradation 3,4,-dihydroxyphenylacetic acid (DOPAC) to homovanillic acid (HVA).
Eight studies investigated the G to A (108 Val to 108 Met) substitution in exon 4 of the COMT gene, a common amino-acid polymorphism that results in low efficacy of the enzyme. Three found that the frequency of the 108Val allele is higher in PD patients than controls in the Japanese 64, 65 and Taiwanese 52 populations, and is augmented by the MAO-B G intron 13 polymorphism. However, these findings were not confirmed in studies of IPD patients in Caucasian, 66 Chinese, 67 Finnish, 68, 69 and American 33 populations, and therefore a conclusion regarding the association of COMT to IPD risk cannot be made (see Table 1 ).
Xenobiotic metabolizing enzymes Cytochrome P450 system enzymes
Researchers have postulated that certain enzymes in the cytochrome P450 (CYP) system provide a protective mechanism from environmental neurotoxins. 70 Several reviews and meta-analysis were performed to determine whether there is an association between cytochrome P450 polymorphisms (CYP2D6, CYP1A1, CYP2C9, CYP2C19, CYP1A2, and CYP2E1) and the risk of PD. [71] [72] [73] [74] [75] [76] The most studied is the CYP2D6 gene, which encodes for the enzyme debrisoquine 4-hydroxylase that metabolizes a wide range of drugs, including MPTP, and has a number of functional polymorphisms. 77, 78 However, the findings were inconclusive. Although two meta-analyses 72, 74 reported a significant association of the poormetabolizer genotype with PD, the other two did not reveal any significant association. 73, 75 In research conducted since the publication of these meta-analyses, no association was found between CYP2D6 polymorphism and the risk of PD. [79] [80] [81] [82] [83] [84] [85] [86] CYP2E1 is an ethanol-inducible enzyme apparently involved in the activation of neurotoxicants that increase oxidative stress (OS), a well-known contributory factor in the pathogenesis of PD. 87 Three studies found no significant differences between PD patients and controls in the distribution of either allelic or genotype frequencies of CYP2E1, 88, 89 suggesting that there is no association between this gene and IPD.
Findings for the CYP1A1 polymorphism were inconclusive. In two studies, the authors found that the relative risk of PD was higher in the CYP1A1 m2 alleles and the CYP1A1 m1m2 and m2m2 genotypes, 89, 91 but these results were not confirmed by two other studies. 83, 92 Overall, these results do not suggest any association between the cytochrome P450 enzymes examined to date and the risk of IPD (see Table 1 ).
Glutathione s-transferases
As mentioned above, OS is widely thought to contribute significantly to the pathogenesis of PD. 87 Given the role of glutathione S-transferases (GSTs) in the conjugation of electrophiles and protection against reactive oxygen species, researchers have suggested that genes encoding the GSTs are good candidates for association studies of PD. 93 Seven studies investigated the role of the GST polymorphisms (GSTM1, GSTT1, GSTP1, and GSTZ1) in the pathogenesis of IPD. Three found that polymorphisms of the GSTM1 and GSTT1 loci resulting from complete gene depletions increased susceptibility to PD. [93] [94] [95] One of these studies further examined the presence of null genotypes of GSTM1, GSTT1, and two polymorphisms of mEPHX in subjects with PD, and found raised levels of homozygosity of the histidine (H) 113 isoform of mEPHX. 95 Analysis of the allele frequencies yielded an increased frequency of the H-allele in these patients. Furthermore, a significantly elevated median age of onset of PD was found among the GSTM1 gene carriers compared to the PD patients with GSTM1 null genotypes. 95 The remaining four studies did not confirm these results, and did not find any association between GST polymorphisms and the risk of PD. [96] [97] [98] [99] The variability of these findings precludes a definitive conclusion regarding the association of GST polymorphism with IPD risk. 
N-acetyl transferase
Seven studies examined the N-acetyl transferase-2 (NAT2) polymorphism. Of the four that focused on polymorphisms of NAT2 in chromosomes 8p21.3-23.1, all reported a higher frequency of the slow acetylator genotype in PD 81, 98, 100 or in young-onset PD. 101 However, the remaining studies, which investigated three mutant alleles M1, M2, and M3 of NAT-2, did not find any differences in allelic frequencies or genotypic distributions between patients with IPD and age-matched controls from the Netherlands, 102 Europe, 103 and the US. 104 Although Tan et al 3 reported that the slow acetylator genotype of NAT2 is associated with IPD risk, findings of recent studies raise doubts concerning this issue.
Other related genes Apolipoprotein E Apolipoprotein E (ApoE) is an important factor in plasma lipid metabolism and a component of several plasma lipoprotein-lipid particles. In all, 25 studies examined the C/T transition converting codon 112 from cysteine (E3) to arginine (E4) in PD patients. Four of them showed that the E4 allele occurred more often in demented 105, 106 and nondemented 107, 108 PD patients, but the others did not find any positive associations. 69, Two additional studies examined the C/G-T/A transition converting codon 158 from arginine (E3) to cysteine (E2), and found that E4 allele E4 had a higher frequency in young 131 and demented 132 PD patients. Taken together, the results of these studies raise doubts as to the association between Apo-E and PD risk.
Mitochondrial genes
Several mitochondrial polymorphisms have been reported in the literature, including the G5460A at mtDNA-encoded reduced nicotinamide adenine dinucleotide dehydrogenase (NADH) 2 (ND2) of complex I and A4336G at the tRNA Gln gene. In a study of the G5460A missense mutation in the ND2 subunit gene of NADH dehydrogenase, a three-fold higher frequency was noted in patients with PD (4/21) compared to controls (5/77). 133 These results were not replicated in later studies. 134, 135 Another study found the mtDNA (A4336G) mutation in two of 23 PD patients and none of 100 age-matched controls (Po0.05). 136 No differences in the frequency of the A4336G polymorphism were noted between IPD patients and controls. 133, 135, 137, 138 A recent study examined the ND3 of complex I enzyme and found that individuals with a specific haplogroup (J or K) demonstrated a significant decrease in risk of PD as opposed to individuals carrying the most common haplogroup (H). Furthermore, a specific single-nucleotide polymorphism (SNP) that defines the J and K haplogroups, 10398G, was strongly associated with this protective effect. 139 These results suggest that ND3 is an important factor in PD susceptibility and could help explain the role of complex I in PD expression; however, more studies and meta-analysis are needed to confirm these data (see also Table 1 ).
Neurotrophic factors
Brain-derived neurotrophic factor (BDNF) Two studies found that homozygosity for the V66M polymorphism of the brain-derived neurotrophic factor (BDNF) gene occurs more frequently in patients with PD than in unaffected controls. 41, 140 However, three other studies conducted in Swedish 141 and Japanese populations did not confirm these results.
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Glial-derived neurotrophic factor (GDNF) In the only study on glial-derived neutrophic factor (GDNF), a potent survival factor for nigrostriatal dopaminergic neurons was found in one of 30 PD patients. However, the alteration did not change the predicted amino-acid sequence, and it was also found in one of 20 patients without PD. 143 Further studies and meta-analysis are needed before we can draw conclusions concerning the effect of neurotrophic factors, and especially genetic variations in BDNF, on the risk of IPD (see also Table 1 ).
Antioxidant enzymes
Antioxidant enzymes are very important in regulating the OS level in cells. 87 Low levels of these enzymes might increase OS and aggravate PD. Indeed, many studies have reported an aberrant OS metabolism within the substantia nigra and other dopaminergic regions of the brain in patients with PD. 87 In one investigation for the possible link between an antioxidant enzyme polymorphism and the risk for PD, the genes encoding for three free-radical detoxifying enzymes were screened: copper/zinc superoxide dismutase, manganese superoxide dismutase (SOD2), and catalase. The authors found an amino-acid substitution (glycine to aspartic acid) in exon 9 of the catalase gene in one PD patient; the same patient also showed a decrease in red blood cell catalase activity. 145 Although similar results were obtained in another study, 146 later investigations did not find any genetic differences in the distributions of allelic frequencies of SOD2 between PD patients and controls. [147] [148] [149] The interpretation of these inconclusive results is problematic.
Linkage-derived candidate genes
Alpha-synuclein This is a presynaptic protein highly and broadly expressed in the brain, but its normal function is unknown. It is also called non-amyloid b component precursor (NACP) because of its localization in amyloid plaques in Alzheimer's disease. Mutations of the alphasynuclein gene have been shown to be relevant in some rare cases of autosomal dominant PD. Among the nine association studies performed to date, only four found significant results for the polymorphism of the promoter region of the alpha-synuclein gene (NACP-Rep1) in German, 131 American, 150, 151 and Japanese 152 populations; the remaining studies from Japan, 153 Ireland, 154 Singapore, 155 Germany, 156 and Italy 157 found no differences from controls. More studies and meta-analysis are needed in order to determine Polymorphism in dopamine-related genes Y Gilgun-Sherki et al unequivocally whether the alpha-synuclein gene polymorphism is associated with IPD risk (see also Table 1 ). Parkin Mutations in the parkin gene, an E3 proteinubiquitin ligase, are known to cause autosomal recessive, early-onset PD. However, the role of polymorphisms in this gene in the risk of IPD was not investigated until recently. In all, 11 studies so far have examined three polymorphisms in the parkin gene: G/A transition in exon 4 (S167N), C/T transition in exon 10 (R366W), and G/C transition in exon 10 (V380L). Seven found that at least one of these polymorphisms was associated with the risk of PD in Japanese, 158, 159 American, 160, 161 Chinese, 162 French, 163 and Australian 164 populations. The rest found that the allelic or genotypic frequencies of S167N, R366W, and V380L were similar in patients with PD and nonaffected controls in Finnish, 69 Taiwanese-Chinese, 165 Spanish, 166 and American 167 populations. According to these results and the criteria presented by Lohmueller et al, 3 the association of the parkin gene and IPD risk is uncertain. Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) This peptide belongs to the de-ubiquitinating enzyme family. A missense mutation in this gene was found to cause PD in a German family. Recent studies of the S18Y polymorphism of the UCH-L1 gene noted an association with IPD risk in Japanese, 41, 140, 168, 169 American, 170 German, 171 and French 172 populations. However, two other studies, from Australia 173 and China, 174 did not, though it was suggested that the S18Y polymorphism might be a weak protective factor against early-onset PD. 174 These results indicate that the presence of the S18Y polymorphism of the UCH-L1 gene might be associated with a reduced risk of IPD. Additional studies and metaanalysis are still required (see also Table 1 ).
Transcription factors
Nuclear receptor related-1 (Nurr1) This is a member of the steroid/thyroid hormone nuclear receptor superfamily that is predominantly expressed in the midbrain, substantia nigra, and ventral tegmental area. Studies in knockout Nurr1 mice indicate that this hormone receptor is essential for the development and differentiation of midbrain dopamine neurons. 175 Therefore, a polymorphism in this gene may well be related to PD risk. One study on the BseRI restriction site of the Nurr1 gene found a homozygous 7048G7049 polymorphism in intron 6 (NI6P) which had a significantly higher frequency in patients with sporadic PD than in healthy control subjects. The clinical features of the homozygous PD patients were similar to those of typical PD. 175 Although these results were replicated by a recent study, 176 two other recent studies of several independent polymorphisms in the sixth and seventh introns in a Swedish 177 and Singaporean 178 population did not find a significant genotype or allelic association with PD. Further research is warranted to determine whether a polymorphism in this gene or other genes encoding for transcription factors involved in the development of the mesencephalic dopaminergic system, such as engrailed gene (En1), Pituitary homeobox 3 (Pitx3), and LIM-homodomain transcription factor 1B (Lmx1b), are associated with the risk of IPD (see also Table 1 ).
Genetic variations with a potential effect on levodopa response Levodopa-induced motor fluctuations in Parkinson's disease The administration of dopamine precursors, particularly levodopa, is the gold standard of treatment for PD. As levodopa is degraded to dopamine by peripheral aromatic amino-acid decarboxylase (AADC), which does not pass the blood-brain barrier (BBB), it has to be co-administered with an AADC inhibitor (carbidopa or benserazide).
The majority of patients respond well to levodopa, at least during the early years of therapy, with individual differences in the degree of symptom improvement. The failure to respond in approximately 15-20% of patients 4 could be the result of population pharmacokinetic and pharmacodynamic heterogeneity in various genes, or misdiagnosis of another parkinsonian syndrome, such as multiple system atrophy (MSA) or progressive supranuclear palsy (PSP) as PD. Furthermore, even in good, stable responders, levodopa control of motor symptoms gradually diminishes after 2-5 years. 179 About 70% of patients ultimately develop a variety of adverse, incapacitating motor manifestations (motor fluctuations and dyskinesias) in response to levodopa treatment. 180 Peak-dose dyskinesias (PDDs) are the most common pattern of levodopa-induced dyskinesia occurring before the fifth year of treatment, 4, 181 in an estimated 30-80% of chronically treated PD patients. [181] [182] [183] PDDs appear during the period of maximal relief of parkinsonian symptoms. They are predominantly choreic in nature, and commonly affect the face, neck, and limbs. 184 When they manifest early in the course of the disease, PDDs are related to peak levodopa concentrations and may be reduced by lowering the treatment dose. Later, however, they occur at levodopa doses needed to induce an anti-parkinsonian effect. These findings suggest that the pharmacologic mechanisms that mediate dyskinesias may differ from those mediating the therapeutic effect of levodopa. 185 Although studies on predictors of the development of dyskinesias have shown discordant results, 4, 186, 187 several risk factors, such as duration of levodopa treatment, disease duration, female sex, young age at onset, and lower tremor scores at baseline, have been identified. These factors, however, only partially account for the appearance of PDD during levodopa treatment, because a considerable proportion of PD patients present never acquire PDD. Thus, a genetic predisposition probably plays a role as well.
Peripheral pharmacokinetics of levodopa
The plasma elimination half-life of levodopa is quite short (about 2 h), which explains the short duration of action (2-3 h) in patients with advanced disease. 188 Therefore, several strategies are used in order to increase the amount of levodopa passing the BBB or to delay the breakdown of dopamine in the brain, such as co-administration of selegiPolymorphism in dopamine-related genes Y Gilgun-Sherki et al line (deprenyl) or rasagiline or other MAO inhibitors. In addition, the peripheral concentration of levodopa can be increased by inhibiting COMT production with entcapone. Figure 1 depicts a suggested polymorphism model of various dopamine-related genes that may affect the response to levodopa. A polymorphism in the gene encoding for AADC might reduce its activity, thereby reducing dopamine levels in the periphery and brain. In addition, polymorphisms in genes encoding for MAO-B and COMT might increase their activity, leading to a reduction in levodopa and, consequently, in dopamine levels in the periphery and brain.
Pharmacogenomics of levodopa
The mechanisms underlying the fluctuations in response to levodopa are only partially understood. They involve, at least in part, polymorphisms in genes that affect levodopa's pharmacodynamic and pharmacokinetic properties (Tables 2,3) .
Pharmacodynamics: dopamine receptors
Oliveri et al 20 were the first to address the possibility that polymorphisms in the genes for DRD1 and DRD2 could be implicated in the appearance of PDD after long-term levodopa use. They found that the frequencies of the 13 and 14 alleles of the DRD2 gene polymorphism were higher in nondyskinetic than in dyskinetic PD patients. The risk reduction of developing PDD for PD patients carrying at least one of the 13 or 14 alleles was 72% with respect to PD subjects who did not carry these alleles. 20 Another study investigated the association between DRD2 and DRD3 gene polymorphisms and the risk of developing motor fluctuations in PD. 189 The authors found that the TaqIA polymorphism located in the DRD2 gene may influence the risk of developing 'wearing off' motor fluctuations. No such association was found for the DRD3 BalI and MspI polymorphisms. 189 Together, these studies support the hypothesis that certain individuals are predisposed to the more frequent motor complications of long-term levodopa use, and that the 20, 189 in the genetic susceptibility to the motor complications induced by levodopa in PD, but this should be further examined.
Blood-brain barrier

Polymorphism in dopamine-related genes and L-DOPA adverse events
The first of two studies on hallucinations in IPD compared the frequency of polymorphisms in the DRD2 and DRD3 genes between patients who had drug-induced hallucinations and those who did not. Two polymorphisms close to DRD2 and one in DRD3 were studied. Findings were negative for the whole group of hallucinating patients, but there was an association of late-onset hallucinations with the C allele of the TaqIA polymorphism 10.5 kb 3 0 to DRD2. This polymorphism may be in linkage disequilibrium with a mutation in DRD2 or a nearby gene that predisposes patients to drug-induced hallucinations later in the course of IPD. 190 Similar results were obtained in a study that examined the frequency of dopamine receptor genetic variants (DRD1, DRD2, DRD3, DRD4) and Apo-E alleles in patients with PD with and without chronic visual hallucinations.
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DRD5 Wang et al
192 used a case-control design to investigate whether the DRD5 T978C polymorphism is associated with the risk of developing motor fluctuations in PD. No differences in overall allelic and genotypic frequencies were noted between motor fluctuators and nonfluctuators. Further study is needed to determine if this or other DRD5 polymorphisms are associated with susceptibility to PD or with the risk of developing motor fluctuations in PD. DAT Another recent study examined whether polymorphisms in the dopamine receptor genes and the DAT gene are predictors of adverse effects of levodopa. Only the nine-copy allele 40-bp VNTR of the DAT proved to be a predictor of psychosis or dyskinesia. 193 These results suggest that DRD2 polymorphism might influence the response of levodopa and contribute to levodopa-induced motor fluctuations (see also Table 2 ). Cholecystokinin (CCK) This is a peptide that modulates the release of dopamine and dopamine-related behaviors in the mesolimbic pathway. Two studies investigated the effect of CCK gene polymorphism on PD risk. 194, 195 The first analyzed genetic variations in the coding and promoter regions of the gene and identified four polymorphic sites (G 196A, C45 T, C1270G, C6662 T). There was a significant difference in the distributions of three of the genotypes at the À45 locus between 116 PD patients (n ¼ 116) and agematched control subjects (n ¼ 95), and between PD patients with and without hallucinations. 194 The other study investigated the association of polymorphisms in CCK and its two receptors (specifically, CCK C45T, CCK-A receptor T779C and CCK-B receptor G1550A) with PD in 160 Chinese patients and an equal number of controls matched for age, gender, ethnic origin, and area of residence. None of the gene polymorphisms were correlated with risk of PD, although the CCK CT/TT genotype was associated with a 4.429-fold increased risk of visual hallucinations in PD. Separate analysis of the CCK-A-receptor and B-receptor polymorphisms yielded no link with hallucinations in PD; however, a combined effect was found in the hallucinating patients who harbored both the CCK CT/TT and CCK-A receptor TC/CC genotypes. Furthermore, PD patients with this genotype had a 5.922-fold increased risk of developing visual hallucinations. 195 These results suggest that the CCK -C45T polymorphism might influence vulnerability to hallucinations in PD patients treated with levodopa (see also Table 3 ).
ApoE An additional study examined whether the Apoepsilon 4 allele is a risk factor for drug-induced hallucinations in nondemented patients with PD. In all, 76% of the patients who harbored the allele had visual hallucinations compared with 23% of those who did not. Treatment with dopamine agonists also contributed to an increased risk of hallucinations. 196 The authors concluded that nondemented PD patients with the ApoE epsilon 4 allele have a high risk of developing drug-induced visual hallucinations. More research is needed in order to validate these results (see also Table 3 ).
Pharmacokinetics
Catechol-O-methyltransferase (COMT)
As previously mentioned, one of the ways to increase the peripheral concentration of levodopa is to inhibit COMT with drugs such as tolcapone. However, patients with PD have a variable response to this medication, and a subset of patients develop severe side effects, such as diarrhea. The variable response may be explained by a polymorphism in the COMT gene, which changes the response to both tolcapone and levodopa (Figure 1) . Indeed, SNP at nucleotide 1947 in the COMT gene has been found to encode for low and high activity, resulting in low-, medium-, and highactivity genotypes.
Early studies reported that COMT activity in erythrocytes of patients with PD is an important determinant of response to levodopa. 197, 198 However, these authors based their findings on only self-reported subjective improvement and did not measure the objective motor response. In addition, no genetic differences were evaluated owing to technological restrictions at the time.
In a more recent study of the relationship between this genotypic variation and the clinical effects of tolcapone changes in levodopa doses and in scores on the United Parkinson Disease Rating Scale (UPDRS), part III (motor subscale) wsa analyzed periodically after the administration of tolcapone. Genotype analysis was performed on seven patients in whom treatment was complicated by diarrhea. Using a linear model approach that adjusted for severity of PD, tolcapone dose, and initial differences in baseline scores, the authors failed to find a significant correlation between Polymorphism in dopamine-related genes Y Gilgun-Sherki et al genotype and improvement in UPDRS score. There was also no significant difference in the change in daily levodopa intake by COMT genotype, and no relationship between diarrhea and COMT genotype. 199 The second recent study investigated COMT genotypes in relation to levodopa response in 73 Korean patients with PD. Findings were compared with 49 control subjects. No significant differences were observed in the distribution of the COMT genotypes among the three groups, and in motor response (evaluated by time to peak response), duration and magnitude of response in the motor part of the UPDRS, and tapping or walking. 200 These studies indicate that the genetic variants of the COMT enzyme investigated so far do not determine the response to tolcapone or levodopa in PD (see also Table 3 ).
Conclusions and future strategies
In recent years, the growing interest in the interactions between genetic and environmental factors has prompted a great number of association studies. These offer a potentially powerful approach to identify genetic variants that influence susceptibility to IPD. Candidate genes have been suggested on the basis of our knowledge of the pathophysiology of PD and include mainly genes related to dopamine metabolism and transport, detoxification of xenobiotics and other toxins in dopaminergic neurons, mitochondrial metabolism, and genes that encode for essential transcription factors or neurotrophic factors involved in the development of the mesencephalic dopaminergic system (see Table 1 ). However, out of 30 genes studied so far, only the MAO-B 4188 bp allele showed significant association with IPD in meta-analysis 24 and only six genes (DRD2, ND3, BDNF, a-Synuclein, UCHL1, and Nurr-1) showed significant association with IPD in several studies and fulfilled the Lohmueller criteria for replication in meta-analysis 3 (see Table 1 ). In addition, only the DRD2 polymorphism appears to influence the response of levodopa and contribute to levodopa-induced motor fluctuations (see also Table 2 ).
Potential reasons for these mixed results might be related to differences in the polymorphisms studied in the same gene, and differences in sample sizes, ethnic groups, and methodologies, which make the synthesis of independent studies almost impossible. Additional potential contributors are population stratification, biological credibility of the gene-disease association, and gene-gene interactions. Furthermore, the inconsistencies may be due to falsepositive or false-negative results, or true variability in association among different populations. Therefore, in order to increase the reliability of future studies, well-designed trials, with large samples 24 and tightly matched controls should be performed, 3, 24 using similar statistical, diagnostic, and molecular methods to enable comparisons, extrapolations, and synthesis of the results from independent individual studies on meta-analysis. In addition, the criteria to be predictive of replication on meta-analysis should be set at a P-value of less than 0.001 for initial positive studies or less than 0.01 when the results are replicated independently by two studies. 3 Furthermore, future studies should also examine novel polymorphisms that might be associated with IPD risk, such as neurotransmitters, for example, enkephalin and neuropeptides, and other dopamine-related genes (eg, dopamine-signaling molecules and dopaminerelated transcription factors). We suggest that the results of association studies on polymorphism of different PD-related genes be assembled in a universal genedatapool in order to facilitate planning of future strategies.
The combination of more association studies with further studies of the molecular mechanism of levodopa 'nonresponders' and levodopa-induced motor fluctuations might improve PD pharmacotherapy and serve as a novel diagnostic tool for PD.
